Akoya Biosciences (AKYA) said Monday that its spatial proteomics platforms will be used to analyze tissue samples as part of the Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity, or MANIFEST, program.
The initiative, funded by the UK Office of Life Sciences and the Medical Research Council, seeks to enhance cancer immunotherapy research through in-depth multi-omic profiling.
The MANIFEST consortium will analyze tissue samples from cancer patients using Akoya's platforms, starting with 6,000 patients with breast, bladder, kidney and skin cancers.
Price: 3.20, Change: +0.42, Percent Change: +15.04
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.